What’s the Value of a Cancer Cure?
By Cyndy Nayer and Leonard Kish When CMS approved Solvadi, Gilead’s $84,000 drug for hepatitis C, the stakes were raised in drug price wars. Two opposing forces, one, a financial push toward lower costs came up against an opposing force of public sentiment. The FDA’s goal of getting 90% of patients moved from costly branded […]
Source: The Health Care Blog - Category: Consumer Health News Tags: THCB Cirrhosis CMS FDA Hepatitis B Hepatitis C HIV PhRMA Solvadi Value-Based Medicine value-driven pharmaceuticals Source Type: blogs
More News: Blogging | Cancer | Cancer & Oncology | Cirrhosis | Health | Health Management | Health Medicine & Bioethics Commentators | Hepatitis | Hepatitis B | Hepatitis C